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ABSTRACT
Numerous studies have contributed to the induction of pluripotency in an abundance of cell
types; however, transfection techniques and efficiency have yielded undesirable outcomes.
Traditionally, the use of viral vectors as a mode of transmission has proven to be efficient in the
induction of pluripotency transcription factors in mammalian cells. The increasing concern is
random insertion of viral components within the host genome due to the viral mode of
replication. The delivery of messenger RNA by cationic lipid delivery vehicles circumvents the
viral concerns and provides an efficient and safe mode of reprogramming. Synthetic mRNA can
be used to initiate endogenous gene expression while maintaining cellular viability in bovine
somatic cells. In this study, bovine fetal fibroblast cells were initially transfected with In Vitro
Transcribed (IVT) RNA expressing Green Fluorescent Protein (GFP) to determine adequate
transfection parameters. Mammalian expression vectors, encoded with either GFP or
pluripotency associated transcription factors OCT4, SOX2, c-MYC, or KLF4, were obtained
from a plasmid repository and used as IVT templates. The mRNA was produced in vitro to
include a 5’ cap as well as a 3’ polyA tail in order to mimic in vivo mRNA packaging. Primary
cultures of bovine fetal fibroblasts were transfected with ivtRNA by way of a cation lipid
delivery vehicle, Lipofectamine, for endocytotic uptake. This process allows the mRNA to
bypass the phospholipid bilayer and enter the cell. The incorporation of modified bases during
the in vitro transcription process was adopted to reduce cell immune response. Addition of small
molecules to enhance the reprogramming process was evaluated as well. The success of ivtRNA
transfection in bovine fetal fibroblast cells was determined through the measurement of cellular
viability, mean fluorescence by flow cytometry under different concentrations of mRNA, and
gene analysis measured by quantitative PCR.

xi

CHAPTER ONE:
INTRODUCTION
Different stem cell types have been described including Adult Stem Cells (ASCs),
Embryonic Stem Cells (ESCs), Induced Pluripotent Stem Cells (iPSCs) and RNA-Induced
Pluripotent Stem Cells (RiPSCs). Adult stem cells can be found in various types of adult, or nonembryonic, tissues and give rise to particular cell lines. The natural purpose of these cells is to
replace diminishing cells during growth or injury (Odorico et al., 2001). Embryonic stem cells
arise from the inner cell mass (ICM) of a developing blastocyst and can give rise to all cell
lineages of the fetus proper; all three major germ layers are produced. ESCs can no longer
differentiate into extra-embryonic, or placental, tissue (Odorico et al., 2001). The third type of
stem cells is known as induced pluripotent stem cells or iPSCs. These cells are derived from
reprogrammed somatic or differentiated cells, and can be utilized in place of ESCs to eliminate
the destruction of embryos while harvesting the ICM. These cells closely resemble the ES cells
in many aspects including the ability to differentiate into different cell-lineages and proliferation.
RiPSCs are simply a type of iPSCs where synthetic in vitro transcribed messenger RNA is
utilized for the induction for reprogramming. Induced pluripotent stem cells have become a very
important tool for the scientific community to study the cellular differentiation process, genetic
manipulations, and regenerative medicine.
Induced pluripotent stem cells can be obtained by an extended list of reprogramming tools. The
reprogramming of somatic cells can be achieved through the delivery of exogenous transcription
factors that stimulate genetic activity similar to that of embryonic stem cells. These exogenous
transcription factors include, but are not limited to OCT4, SOX2, NANOG, c-MYC and KLF4
(Takahashi and Yamanaka, 2006). The introduction of these previously silenced embryonic
transcription factors can up-regulate their own endogenous expression. While, theoretically, the
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increased expression should be easily attainable, there are numerous cellular hurdles to
overcome. These hurdles tend to lead to differences in efficiency and at times successes of
various modes of cellular reprogramming to pluripotency. These modes of reprogramming
utilize various cellular processes to increase endogenous expression of known pluripotency
factors. Viral transduction is commonly used in research as the mode of choice for the delivery
of these factors. The virus encoding the desired sequence is incubated with the target cells to be
reprogrammed. The cells are reprogrammed quite efficiently and have desirable results, though
the random insertion of viral particles into the host genome remains undesirable. Viruses with
alternate modes of replication have been used to minimize this random insertion with mixed
results, including incomplete reprogramming (Takahashi and Yamanaka, 2006; Fusaki et al.,
2009). There have been other attempts to avoid this random insertion, such as the addition of
specific proteins to the target cells (Kim et al., 2009a; Zhou et al., 2009; Cho et al., 2010). While
this circumvents the insertion issue, it can be a difficult process to achieve due to the difficult
purification processes. Synthetic messenger RNA transfection has the ability to avoid both
random insertion into the host genome and rigorous purification protocols.
Synthetic RNA transfection has been an invaluable tool in understanding the mammalian
genome due to its ability to deliver exogenous protein without mutagenic effects caused by
double stranded DNA. A common problem associated with the introduction of exogenous
mRNA into mammalian cells is the stimulated interferon response. This innate immune response
can be avoided with the addition of modified bases during the in vitro transcription process of
synthetically derived mRNA (ivtRNA). The bases cytidine triphosphate (CTP) and uridine
triphosphate (UTP) are replaced with 5-methylcytidine-5’-triphosphate (5-Methyl-CTP) and
pseudouridine-5’-triphosphate (Pseudo-UTP) during in vitro transcription. Cellular
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reprogramming is achieved by the delivery of this ivtRNA into the cytoplasm. Previous cellular
reprogramming experiments lacking modified bases resulted in increased toxicity and decreased
cellular viability, which lead to the incorporation of modified bases (Warren et al., 2010). The
decreased immune response by the inclusion of modified bases may be advantageous in a variety
of applications, from the introduction of TALENS or zinc finger nucleases for genomic editing
to increased efficiency of the development of induced pluripotent stem cells (Hockemeyer et al.,
2011).
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CHAPTER TWO:
LITERATURE REVIEW

Embryonic Stem Cells
ESCs are derived from the inner cell mass (ICM) of a developing blastocyst. These cells
will eventually differentiate into hundreds of various cell types that will unify to form an entire
fully functional organism. The genetic programming needed to differentiate into a completely
functional cell type is contained in each of these embryonic stem cells. There are very specific
epigenetic triggers that must occur to determine which path is to be followed. The primary
distinction of embryonic stem cells from trophectoderm cells is the change in cellular pathways
and expression. The inner cells of the blastocyst receive cell surface signals impeding cellular
blocks preventing pluripotent transcription factor Oct4 (Gilbert, 2010). The pluripotency of these
embryonic stem cells is dependent on Oct4 gene expression. When Oct4 expression is decreased
or prevented, differentiation pathways are activated.
Distinctive Properties of Embryonic Stem Cells
Embryonic stem cells possess a truly unique quality that allows complete differentiation
of a cell down numerous developmental pathways. This quality is diligently sought after to cure
and/or treat disease and further the success of regenerative medicine. This quality is known as
pluripotency. Pluripotency can be defined as the ability of a cell to give rise to all three germ
layers of the embryo proper while not producing the cells confined to extra-embryonic, placental
tissue. Cells that that have the ability to become both the embryo proper and the extra-embryonic
tissue are known as totipotent. The cells that make up the zygote are totipotent and will
eventually segregate into two specific cell types: ICM and trophoblast cells.
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Stem cells possess another interesting quality of self-renewal. Few cells possess this
remarkable feature. Many cells have a predetermined number of cell divisions and will
eventually terminally differentiate; they will no longer self-renew. An example cell type
expressing terminal differentiation is neuronal cells. These cells will develop and differentiate
down a particular path and arrest at a pre-determined point. If damaged, these cells cannot repair
themselves to be made new again. Regenerative medicine had focused on therapeutic care
involving such damage, like spinal injuries, for some time now. The desire to capture these
qualities and facilitate safe and efficient reproduction has been sought after by many research
institutions. The study of numerous diseases as well as normal zoological development is made
possible by the production of cells containing these qualities.
Mouse ESCs were first isolated and characterized in 1981. There were two characteristics
of interest: infinite proliferation, and the ability develop into various specialized cell types
(Evans and Kaufman (1981). Human ESCs were first isolated in 1998 by James Thompson at the
University of Wisconsin. He utilized the characteristics developed previously to verify that the
cells he had isolated were in fact ESCs. The cells possessed the ability to both infinitely
proliferate and develop into various cell types (Thomson et al., 1998).
The disadvantage to possessing these cells is that in order to obtain them, the embryo
harvested for embryonic stem cell retrieval is ultimately destroyed. Once the inner cell mass is
removed from the blastocyst, it can no longer proceed with normal development to form an
organism. This area of medicine has, of course, developed attention and ethical concerns in both
the public and private sectors. Media and political attention have caused a decrease in research
utilizing human embryos. The drive to eliminate embryo destruction led to the development of
induced pluripotent, or reprogrammed cells.
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Adult Stem Cells
Adult stem cells (ASCs) are present in the body of an individual and are used to replace
cells lost due to growth or damage (Stein, 2011). Some tissues in the body have an abundant
ability to self-renew, indicating an increased source of adult stem cells for replenishment; others
do not regenerate as actively (Wagers and Weissman, 2004). These adult stem cells can be found
in many tissues such as bone, marrow, skin, muscle, and fat. These cells are referred to as “adult”
but are not restricted adult organisms and can occur in a variety of non-embryonic tissue.
A specialized form of ASCs used in research is hematopoietic (HSCs) or Mesenchymal
stem cells. A single cell derived from bone marrow has the ability to give rise to different blood
cell types (Till and McCulloch, 1961). ASCs can be characterized as multi-, oligo-, or unipotent,
and can give rise to a limited number of cells—and, in some cases, only one very specific cell
type (Wagers and Weissman, 2004). These cells are usually restricted to a particular cell type or
group from which they are located, and have been the reason for limited clinical applications of
ASCs.
Induced Pluripotent Stem Cells
Somatic or differentiated cells have the ability to be reprogrammed into a less
differentiated, pluripotent-state and are referred to as induced pluripotent stem cells or iPSCs.
These cells become like embryonic stem cells—regaining the ability to proliferate—and can be
stimulated to become other cell types. IPSCs are a conduit for reprogramming methods resulting
in a desired cell type. There are numerous epigenetic modifications that take place when a cell
line transforms from a terminally differentiated state, such as a somatic cell to an embryoniccell-like state. The cells gain the ability to change from unipotent to pluripotent: a precursor to
many cell types instead of just one. The mechanisms within cellular reprogramming are intricate
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and somewhat illusive. The understanding and manipulation of these mechanisms provide an
array of scientific benefits. Attempts have been made in several species to reprogram somatic
cells to pluripotency and become embryonic stem cell-like (ES cell-like) colonies. This feat was
first completed in 1981 by culturing the inner cell mass of mouse embryos (Evans and Kaufman,
1981). Later, Yamanaka and colleagues established the known four-factor cocktail of
transcription factors—Oct3/4, Sox2, c-Myc, and Klf4—needed to induce pluripotency in mice
and human fibroblasts (Takahashi and Yamanaka, 2006; Takahashi et al., 2007). Due to the
apparent conservation of the sequences, the induction of pluripotency has been successful in
other species such as rat, pig, rhesus monkey, rabbit, and canine (Liu et al., 2008; Esteban et al.,
2009; Ezashi et al., 2009; Liao et al., 2009; Honda et al., 2010; Shimada et al., 2010). Bovine
embryonic fibroblasts recently have been reprogrammed to pluripotency utilizing a retroviral
vector in 2011(Han et al., 2011). The viral transfection process is very efficient, but has caused
concern in the domestic animal industry due to its possible integration into the genome. Attempts
are being made to eliminate viral components in the induction of pluripotent stem cells.
RNA Induced Pluripotent Stem Cells
A novel approach to eliminate the use of viral vectors in pluripotency induction is the use
of in vitro transcribed mRNA (ivtRNA) as the pluripotency stimulating molecule. This ivtRNA
encodes one of the known pluripotent transcription factors and can be combined with others for
increased efficiency of induction. The ivtRNA is then encapsulated within a cationic lipid
delivery vehicle for enhanced delivery into the cell. The host cell can then produce the
transcription factor while eliminating the fear of viral contaminants. RNA-induced pluripotent
stem cells can safely deliver the much sought-after qualities of ESCs while simultaneously
eliminating the destruction of embryos.
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Benefits of Stem Cells in Research
Stem cells possess the ability to differentiate into separate cell lineages and can
contribute greatly to the scientific community. The benefits of safe iPSCs are numerous. One of
the benefits is regenerative medicine, which is designed to replace lost or damaged cells due to
illness or injury (Hipp and Atala, 2008). The benefits affect human therapeutic applications,
alleviated ethical concerns with the destruction of embryos for stem cell harvest, provision of a
higher quality and less differentiated cell to be used for SCNT, and higher quality genetically
modified livestock with no viral carryover. The ES-like colonies can be developed with both
efficient production and safe transmission lacking integration into the host genome. The
elimination of viral integration and increased colony production are useful research goals for
commercial applications.
Gene Expression of Embryonic Stem Cells
OCT4
There are numerous pluripotent transcription factors associated with embryonic stem
cells. These include OCT4, SOX2, c-MYC, and NANOG. OCT4 is a part of the POU (Pir-OctUnc) transcription factor family that regulates gene expression by binding to a specific domain
containing an AGTCAAAT consensus sequence (Schöler et al., 1991; Pesce and Schöler, 2001;
Jin et al., 2002). Many sources suggest the presence of OCT4 is required to obtain any of the
other transcription factors, and is responsible for maintaining pluripotency (Niwa et al., 2000;
Pesce and Schöler, 2001; Jin et al., 2002; Babaie et al., 2007). Overexpression of OCT4 can
stimulate ESCs to differentiate into endoderm or mesoderm type cells (Niwa et al., 2000;
Rodriguez et al., 2007) while reduced expression induces trophectoderm differentiation (Niwa et
al., 2000; Hay et al., 2004; Matin et al., 2004; Zaehres et al., 2005; Babaie et al., 2007). The
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diagram below illustrates the changes in OCT4 expression throughout development (Jin et al.,
2002). Positive OCT4 expression

Figure 2.1 OCT4 Expression During Development (Jin et al., 2002)
can be seen in the zygote and morula, but later expression becomes isolated to the ICM of the
blastocyst. The outer trophoblastic cells are expected to test negative for OCT4. Once ESCs
differentiate into separate lineages, the OCT4 expression is suppressed.
Due to the importance of OCT4 in maintaining pluripotency, it is crucial to limit its
expression when cells require differentiation instead of proliferation. “Oct4 activity must be
tightly regulated to ensure the continuity of the germline and proper differentiation of various
tissues and organs” (Jin et al., 2002). OCT4 works in conjunction with other transcription factors
to assist in maintaining pluripotency via stimulation and repression of important genes within the
genome. OCT4 is a part of the POU (Pir-Oct-Unc) transcription factor family that regulates gene
expression by binding to a specific domain containing an AGTCAAAT consensus sequence
(Schöler et al., 1991; Pesce and Schöler, 2001; Jin et al., 2002).
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SOX2
Another transcription factor proven important in early development of ESCs is SOX2.
This factor plays a role in maintaining pluripotency but can also participate in the differentiation
of ESCs. SOX2 expression is not restricted to the inner cell mass and epiblast, but is also found
to be expressed in neural tissues, extra-embryonic ectoderm, gut endoderm, esophagus, and
trachea (Wood and Episkopou, 1999; Avilion et al., 2003; Williamson et al., 2006; Adachi et al.,
2011). Prior to implantation, SOX2 plays a significant role in the formation of trophectoderm
and neural development (Avilion et al., 2003; Kelberman et al., 2006; Taranova et al., 2006).
Although expression has been reported in numerous locations, SOX2 continues to play a
fundamental role in maintaining the inner cell mass. Overexpression of SOX2 can lead to nonspecific lineage differentiation, neuronal formation, and/or massive cell death (Mitsui et al.,
2003; Zhao et al., 2004; Kopp et al., 2008; Adachi et al., 2011). If repressed, SOX2 can induce
the formation of trophectoderm (Masui et al., 2007). An impediment in the continuation of the
ICM maintenance as well as defective development of trophoblast cells was observed in Sox2deficient mice (Avilion et al., 2003). These observations suggest the widely diverse role of
SOX2 in maintenance and differentiation during the earliest stages of development.
NANOG
There is another very important transcription factor that exists within the pluripotency
network known as NANOG. This transcription factor is essential in blocking differentiation in
embryonic stem cells. The development of ESCs occurs in cycles of expansion, or proliferation,
and differentiation. There are specific signals that must be present for the cell to follow one path
or another. The combined expression of OCT4 and SOX2 transcription factors is thought to
activate NANOG by binding to the NANOG promoter thus activating transcription. NANOG
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gains the ability to, in turn, further activate itself, OCT4, and SOX2 (Chickarmane et al., 2006;
Wu et al., 2006; Storm et al., 2007; Takao et al., 2007). A continuous loop is formed containing
numerous interweaving pathways that would both activate and repress expression in a very
specific manner. A recent paper suggests possible auto-repression of NANOG to regulate
transcription switching independent of OCT4 and SOX2 (Navarro et al., 2012). It is suggested
that “in contrast to the accepted model, [there is] a negative correlation between the level of
Nanog mRNA and protein…and the level of transcription of the endogenous Nanog
locus…suggesting that NANOG negatively affects transcription [of the] Nanog gene” (Navarro
et al., 2012). Once NANOG expression is repressed, its absence stimulates its own production;
but when in abundance, NANOG again undergoes auto-repression through unknown binding
sites (Navarro et al., 2012). OCT4 and SOX2 have been shown to activate NANOG
transcription through joint binding, but the OCT4/SOX2 stimulation pathway may be
independent of the NANOG-Nanog-induced pathway (Navarro et al., 2012).
c-MYC
In 2006, Takahashi and Yamanaka isolated four transcription factors needed to stimulate
pluripotency in somatic cell reprogramming. These four factors were OCT4, SOX2, NANOG,
and c-MYC. The first three are known to have a close relationship for intertwining activation and
repression of one another, as previously stated. Transcription factor c-MYC plays a role in the
efficiency in which these factors can induce pluripotency in somatic cells, but it is not actually
required for the process to take place (Nakagawa et al., 2008; Wernig et al., 2008). However, cMYC is a known oncogene that has the potential to become mutated and stimulate infinite
proliferation. It is this fact that guides researchers to refine an efficient production process for the
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induction of pluripotency that excludes the c-MYC transcription factor from the reprogramming
cocktail for fear of inducing cancer.
KLF4
The Kruppel-like factor 4 is a key factor in cellular reprogramming to pluripotency
(Evans et al., 2007). This factor is tightly bound to the OCT4 and SOX2 synergistic network of
signaling pathways and influences the production of the much needed transcription factor,
Nanog (Wei et al., 2009). KLF4 can play the role of both an activator and repressor of the
transcriptional pathway to pluripotency by regulating proliferation and differentiation (Evans et
al., 2007). This transcription factor includes three zinc fingers at the C terminus that play a
crucial role in the activation and transcription of the Nanog promoter (Wei et al., 2009). KLF4
has been reported to be a tumor suppressor within gastrointestinal cancers (Dang et al., 2000). It
is interesting to note, however, that there are negative forms of KLF4 that can suppress or
decrease cellular reprogramming to pluripotency. Studies have reported that the introduction of
these negative forms can significantly reduce cellular reprogramming (Wei et al., 2009).
Numerous research strategies attempt to eliminate KLF4 from the reprogramming cocktail due to
its identification as an oncogene associated with breast cancer (Foster et al., 2000). This factor
has both tumor-suppressive and tumor-stimulatory characteristics and may lead to its final
elimination within the reprogramming cocktail, but its intimate relationship with pluripotency
factors OCT4 and SOX2 will secure its position in many reprogramming protocols.
Somatic Cell Nuclear Transfer
The process of somatic cell nuclear transfer fuses an enucleated oocyte with a fully
differentiated somatic cell to produce an embryo, and even live offspring (Gurdon et al., 1958;
Campbell et al., 1996; Wilmut et al., 1997). The donor cell must undergo a series of epigenetic
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changes to become reprogrammed into an embryonic state when placed inside or fused with an
oocyte. Once the cell has been reprogrammed, developmental processes can then occur to
develop cells of many lineages. If a donor cell population to be used for SCNT has already been
reprogrammed, it could jumpstart the developmental process, thus increasing efficiency.
Early experiments tested the theory of cells maintaining the genetic material required to
support different cellular lineages. This was evaluated by transplanting nuclei from living cells
into the eggs of frogs (Briggs and King, 1953; Gurdon et al., 1958; Gurdon, 1962a). The birth of
Dolly in 1997 exhibited the idea that a differentiated cell maintained the genetic ability to
support the complete development and maturation of an adult mammal through the process of
somatic cell nuclear transfer (Wilmut et al., 1997). The environment within the oocyte supports
the epigenetic reprogramming of the transferred nucleus and has the potential to become
totipotent, developing into a fully developing embryo. The concern in this process is incomplete
cellular reprogramming as the transferred nucleus undergoes epigenetic modifications. These
early incomplete reprogramming processes often lead to problematic placental development,
large offspring syndrome, and shorter life span (Yang et al., 2007; Gurdon and Wilmut, 2011). In
earlier amphibian experiments, the success of the development process was thought to be
influenced by the donor cell for transfer (Briggs and King, 1960). The earlier in the
developmental pathway a donor cell is harvested, the more normality exhibited in the transfer
development (Briggs and King, 1957; Gurdon, 1962b). The concern leads to the requirement of a
less differentiated cell as the nuclear donor for somatic cell nuclear transfer. This lessdifferentiated cell can be obtained from embryonic cells, though they may not be available for
isolation. A completely reprogrammed somatic cell exhibiting embryonic stem cell
characteristics and gene expression is thought to be an alternate source of nuclei for transfer. It is
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at a less-differentiated state and requires less reprogramming stimulation by the oocyte.
Efficiency of SCNT and decrease in problematic developmental concerns has the potential to be
achieved with this previously reprogrammed nucleus.
Reprogramming by Viral Transfection
While true embryonic stem cells are isolated from the inner cell mass of the embryo,
numerous processes have been defined to obtain cells whose characteristics are nearly identical.
Cellular reprogramming by viral transduction is the most accepted method for reprogramming.
The viral particles are easily accessible and can be altered for very specific uses. The viral
particles encoding desired sequences are introduced to the cell culture where they are taken up
by the cells. The sequences are integrated into the genome and are expressed by the cell to allow
reprogramming. When compared to mRNA transfection this approach is characterized by a
considerable decline in workload. The transduction is conducted once or twice at the beginning
of the reprogramming trial compared to daily mRNA transfections during the weeks of cellular
reprogramming. The daily transfections not only are more labor intensive, but also increase the
likelihood of contamination with excessive handling. The viral method demonstrates increased
efficiency when compared to other reprogramming methods, though efficiency can be measured
in various ways. The total number of cells reprogrammed from the starting material remains
around 1% but can be increased considerably compared to other methods. According to a recent
paper, the mRNA reprogramming method is equally or more efficient than the accepted viral
methods (Warren et al., 2010).
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Problems Associated with Viral Transfection
The possible integration into the host genome is the major concern in viral-mediated
reprogramming. The many human and/or domestic animal applications do not allow genetic
carry-over of viral material. The numerous studies performed utilizing viral reprogramming
generated mixed conclusions concerning the removal of viral particles with extended culture.
Viral particles are difficult to completely eliminate from the cell lineage.
DNA-Free Transfection Methods; Cell-Penetrating Peptide Moieties and RNA-Based Viral
Systems
The mode of transmission most commonly utilized is viral transmission due to its
increased efficiency in the production of pluripotent stem cell lines. Other modes include, but are
not limited to, serial protein transduction (Kim, D. et al.,2009; Zhou et al., 2009), non-integrating
Sendai virus (Fusaki et al., 2009), chemical induction paired with a single transcription factor
(Li, Y. et al., 2011), and the novel approach of synthetic modified mRNA delivery (Warren et
al., 2010). These methods all utilize different mechanisms for successful cell integration. The
method of transmission to be utilized commercially or on a grand scale should be efficient in
reprogramming and formation of iPSC colonies, as well as safe for the host genome posttransmission. The viral method is highly efficient, but it is the least safe of all methods. The
possible integration into the host genome is of the greatest concern, especially if the cells are to
be used in human therapeutic treatments or in the formation of genetically modified livestock.
The random insertion of the viral components into the host genome carries numerous possible
genetic complications. Protein transduction is safe as it pertains to the host genome, but is
difficult to harvest and purify in quantities required for reprogramming procedures (Zhou et al.,
2009). The Sendai virus has an RNA-based life cycle and theoretically should not integrate into
the host genome. However, the purification processes are very rigid to ensure no viral carryover.
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This harsh process can decrease the overall efficiency of the Sendai virus as a carrier vehicle
(Fusaki et al., 2009). However, synthetic mRNA can be directly administered to induce
pluripotency without integration into the host genome and provide efficient iPSC production
(Warren et al., 2010).
In Vitro Transcribed Messenger RNA Delivery for Reprogramming
Previous research has focused on inducing pluripotency of somatic cells to avoid the
destruction of embryos due to its obvious ethical concerns. The addition of transcription factors
normally present in the embryonic cells is fundamental to the reprogramming process. The
methods of including these factors have varied from viral transmission, bacterial plasmid
introduction, and addition of cellular extracts in culture. While all have been successful in
developing pluripotent stem cells, growing concerns center on factor carry-over from these
methods. The addition of synthetically derived messenger RNA encoding known pluripotent
transcription factors can eliminate these genetic concerns. Desired sequences are synthesized
from a template and packaged to ensure acceptance by the target cell. The transcripts contain a 5’
guanosine cap analogue and 3’ polyadenylation similar to the packaging acquired in vivo for
translation. The in vitro transcribed transcript, ivtRNA, is delivered into the cell by either lipidmediated delivery vehicle or electroporation. Once the sequence crosses the cell membrane, it
can be taken up by the cellular machinery for translation. The increase in desired transcription
factors has the ability to increase or decrease endogenous production. Repeated transfections
using exogenous synthetic messenger RNA is required to achieve this effect. The encouraging
characteristic of ivtRNA is that it does not integrate into the host genome and does not carry over
into subsequent generations.
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Enhanced Reprogramming Using Small Molecules
Reprogramming of somatic cells has proven to be inefficient, leading to the discovery of
small molecules for enhanced reprogramming. The small molecules can either replace current
transcription factors, or simply be added to the culture medium for increased reprogramming
efficiency. The replacement of oncogenic transcription factors such as c-Myc and Klf4, as well
as the elimination of viral vectors, can be useful in therapeutic applications. The eventual
elimination of possible genetic carryover and integration is the goal of small molecule
reprogramming methods. A recent study may have overcome this barrier by reprogramming
mouse somatic cells to pluripotency by small molecules alone (Hou et al., 2013).
Small molecules have the potential to stimulate or inhibit critical developmental
pathways for the induction or maintenance of pluripotency, and are typically organic compounds
measuring less than 500 Daltons in size. These small molecules can be genetic factors, signaling
molecules, and chemical inhibitors that can replace and/or enhance the predetermined core
transcription factors required for reprogramming. Some non-oncogenic transcription factors can
replace oncogenic transcription factors in reprogramming. Klf4 and c-Myc can be replaced with
Nanog and Lin28 respectively (Yu et al., 2007). Certain cell types readily express core
transcription factors endogenously and require less exogenous stimulation to achieve
reprogramming. Neural progenitor cells (NPCs) contain endogenous Sox2 in relatively high
levels and can be reprogrammed to pluripotency without addition of exogenous Sox2
transcription factors (Eminli et al.; Duinsbergen et al., 2008; Jeong Beom et al., 2008).
The addition of small molecules can enhance a reprogramming procedure by affecting
various cellular processes. One process commonly targeted is the G9a histone methyltransferase
pathway (HMT). Histone modifications such as lysine methylation can greatly affect chromatin
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accessibility during mitosis and transcription. These modifications can have various
developmental effects. Specifically, histone H3 Lysine9 (H3K9) methylation is responsible for
chromatin repression for developmentally important genes and is catalyzed by G9a HMT.
According to a previous study, “the euchromatic H3-K9 methylation regulated by G9a is
involved in the transcriptional silencing of developmentally regulated genes” (Tachibana et al.,
2002). The inhibition of G9a HMT can lead to the up-regulation of pluripotent transcription
factors previously silenced. DZNep, a S-adenosyl homocysteine (SAH) hydrolyse inhibitor, has
been reported to increase reprogramming efficiency when combined with other small molecules
(Hou et al., 2013). The increase in SAH interferes with the lysine methylation process required
for repression. One small molecule that has been shown to inhibit G9a histone methyltransferase
(HMT) is BIX-01294, which does not compete with cofactor S-adenosylmethionine (SAM) (Shi
et al., 2008). BIX-01294 has been reported to enhance cellular reprogramming to pluripotency
and has the ability to replace Sox2 when reprogramming mouse neural progenitor cells (NPCs)
(Shi et al., 2008). The chemical inhibitor, NuP0148 (NuPotential, Baton Rouge, LA), inhibits
G9a HMT by binding to the S-adenosylmethionine (SAM) binding site within the enzyme. This
inhibits the transfer of a methyl group to the histone lysine tail. The obstruction of the SAM
binding site may be advantageous to simply increase the ratio of SAH to SAM present within the
system. Developing small molecule inhibitors requires specificity and the SAM binding site
seems to be an exceptionally good landscape. This inhibition then leads to increased
reprogramming by reactivating the previously silenced Oct4 heterochromatin region. The
reactivation of the gatekeeper transcription factor, Oct4, jumpstarts cellular reprogramming to
pluripotency.
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In addition, glycogen synthase kinase 3 (GSK3) and mitogen-activated protein kinase
(ERK1/2) pathways can be inhibited to promote cellular reprogramming. The combined
inhibition of these pathways can lead to reactivation and stabilization of the core pluripotent
transcriptional circuitry required for differentiated cellular reprogramming. GSK3 inhibitor
CHIR99021 combined with ERK1/2 inhibitor PD0325901 has been shown to enhance
reprogramming to pluripotency (Silva et al., 2008).
Safety and Efficiency of Reprogramming to Pluripotency: Future Outlook
Pluripotency can be achieved by numerous reprogramming methods, all of which result
in different yields and standards of efficiency. The following diagram has been modified to
illustrate the position these methods place in terms of safety and efficiency (González et al.,
2011). Efficiency is not a term uniformly agreed upon, but generally refers to a yield of colonies
from a limited amount of resources and time. Safety refers to the genetic carryover associated
with the reprogramming method. The viral methods have proven to be the most efficient in terms
of colony yield, but have yet to completely eliminate genetic carryover. Methods of
reprogramming such as the addition of proteins associated with pluripotency are quite safe.
Concern with genetic integration and long-term expression is absent; however, the complicated
processes associated result in low yield. A previous study utilized synthetic messenger RNA, or
ivtRNA, as a reprogramming tool with efficiency results comparable to viral methods (Warren et
al., 2010). The lack of genetic integration and/or random insertion places this reprogramming
method at the peak of efficiency and safety.
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Figure 2.2 Efficiency and Safety Comparison of Cellular Reprogramming Methods (modified
from (González et al., 2011)
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CHAPTER THREE:
RESPONSE OF BOVINE FETAL FIBROBLASTS TO PLURIPOTENCY
INDUCTION WITH IN VITRO TRANSCRIBED MRNA
Introduction
Cellular reprogramming can be achieved by the delivery of mRNA into a biological
system. The introduction of RNA can either up-regulate or “knock-down” gene expression in a
very specific manner. The introduction of exogenous mRNA eliminates the transcription process
required with the introduction of DNA into the cell. The new sequence can be delivered into the
cytoplasm for immediate translation. There are two methods of mRNA delivery: electroporation
and cationic lipid-mediated delivery vehicles (Van Tendeloo et al., 2001; Audouy et al., 2002).
Electroporation is the process in which genetic material is introduced into the cell by pores in the
cytoplasm caused by electric pulses. This process efficiently delivers the genetic material, but is
not optimal for repeated uses. Though electroporation has proven to be successful, we utilized
the second approach due to the need of repeated exposure to exogenous factors.
Repeated electroporation can damage the cells and hinder proliferation and expansion,
thus inhibiting reprogramming. Cationic delivery vehicles are liposome-type molecules that will
spontaneously interact with the cell surface to introduce genetic material to the cytoplasm. This
method utilizes the fact that cells cultured in vitro have a net negative charge (Dwarki et al.,
1993). The lipid delivery vehicles contain a positive charge and are naturally attracted to the cell
surface. Incubation of cationic lipid-delivery vehicles containing genetic information with target
cells can initiate cellular reprogramming with the uptake of mRNA.
The method of mRNA introduction can be easily managed, but maintaining sufficient
volumes of RNA can be problematic. RNA rapidly degrades and is less stable than its DNA
counterpart. Messenger RNA can be synthesized and quantified in vitro to obtain an adequate

21

amount for the transfection. This in vitro transcribed messenger RNA is also packaged similar to
the form found in vivo in the cytoplasm. The addition of a 5’ cap and poly-A tail is utilized in the
in vitro transcription process to mimic its natural form to be translated.
Reprogramming and the induction of pluripotency using in vitro transcribed mRNA
transfection have proven successful in human and murine cell lines (Warren et al., 2010). The
objective of this study was to deliver ivtRNA to bovine fetal fibroblasts in a manner consistent
with induced pluripotency. Green fluorescent protein (GFP) ivtRNA was delivered and
fluorescence was measured by flow cytometry to determine a desirable transfection
concentration and time course. Cellular viability was examined to address cytotoxicity.
The stimulation of endogenous bovine OCT gene expression is critical in the cellular
reprogramming process. OCT4 has been referred to as the “Gatekeeper in the beginnings of
mammalian development” (Pesce and Schöler, 2001). OCT4, a part of the POU domain, remains
expressed throughout development, but down-regulation becomes simultaneous with cellular
differentiation (Jin et al., 2002). The up-regulation of endogenous OCT4 is necessary to
jumpstart the reprogramming network, including SOX2 and Nanog. OCT4 transcription factor is
normally expressed early within embryo development—almost exclusively within the
blastomeres. As the organism develops, OCT4 expression becomes confined to germ cell
expression (Pesce and Schöler, 2001). The differentiation process requires activation of specific
genes and silencing of others. As the developmental process continues, OCT4 expression
becomes limited in the organism as a whole. The silencing of genes required for pluripotency
and rapid cell division is mandatory as a cell becomes more specialized. The specialized—or
differentiated—cell becomes distinct, producing transcripts specific to its cell type. The downregulation of embryonic genes becomes necessary for the cell to become specialized.
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In vitro transcribed mRNA transfection has proven an invaluable tool in understanding
the mammalian genome due to its ability to deliver exogenous protein without mutagenic effects
that may be caused by double-stranded DNA. However, a common problem associated with the
introduction of exogenous mRNA into mammalian cells is the stimulated interferon response.
Toll-like receptors on the surface of mammalian cells are able to recognize foreign genetic
patterns and initiate an immune response (Uematsu and Akira, 2007). This response involves a
change in gene expression to ultimately result in antigen-specific immunity (Takeda and Akira,
2005). Toll-like receptors have the ability to recognize a vast number of organisms in a very
specific manor, including viruses, and proceed in step for their elimination (Uematsu and Akira,
2007). The signaling pathway associated with this invoked immune response is quite elaborate
and has the ability to become lethal to cells in culture. Experiments within this manuscript
utilizing ivtRNA lacking modified bases resulted in toxicity to the point of early termination of
the time course. Previous cellular reprogramming experiments lacking modified bases resulted in
increased toxicity and a decrease in cellular viability, which lead to the incorporation of modified
bases (Warren et al., 2010). Essentially, the innate immune response can be avoided with the
inclusion of modified bases during the in vitro transcription process of in vitro derived mRNA.
The bases cytidine triphosphate (CTP) and uridine triphosphate (UTP) are replaced with 5methylcytidine-5’-triphosphate (5-Methyl-CTP) and pseudouridine-5’-triphosphate (PseudoUTP) during the in vitro transcription process. Cellular reprogramming is achieved via the
delivery of this modified ivtRNA into the cytoplasm of a cell by a cationic delivery vehicle,
Lipofectamine. The innate immune response is not invoked and the target cells continue to
proliferate.
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The process of cellular reprogramming may be enhanced with the inclusion of small
molecules in the experimental regime. These small molecules have the ability to promote or
enhance reprogramming by direct involvement in the reprogramming mechanisms themselves.
The small molecules, or inhibitors, utilized include MEK inhibitor PD0325901, GSK3 inhibitor
CHIR99021, and G9a histone deacetylase inhibitor NuP0148. The combination of PD0325901
and CHIR99021 has been shown to promote pluripotency when combined with LIF (Silva et al.,
2008). PD0325901 has been reported to promote growth in iPSCs and possibly inhibit growth in
non-iPSCs (Shi et al., 2008). Histone deacetylase inhibitors have been shown to enhance cellular
reprogramming in bovine somatic cells (Staszkiewicz et al., 2013). The combination of these
inhibitors has the potential to enhance the reprogramming process and possibly lead to the
replacement of pluripotent transcription factors all together.
Primay endpoint of this evaluation is to report the induced expression of endogenous
pluripotency genes. This induction is the first step in cellular reprogramming to pluripotency.
Stimulation of endogenous pluripotency transcription factors suggests that the epigenetic
modifications required for altered gene expression have been initiated, and the target cells are on
the path to becoming ESC-like cells.
Materials and Methods
Templates were obtained from Addgene as plasmids containing sequences encoding GFP
or human OCT4, SOX2, KLF4, c-MYC. Plasmid inserts were excised by restriction enzyme
prior to in vitro transcription utilizing mMESSAGE mMACHINE Kit (High Yield Capped RNA
Transcription Kit) according to manufacturer protocol. The reaction was packaged with the Poly
(A) Tailing Kit (Applied Biosystems AM1350) followed by purification using MEGAclear spin
columns (Applied Biosystems AM1908). KMOS (Klf4, c-Myc, Oct4, Sox2) stoiciometry of
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1:1:3:1 cocktail was utilized. RNA transfections were carried out using Lipofectamine®
RNAiMAX Reagent. Modified 2X NTP/CAP (5-methylcytidine-5’-triphosphate (5-Methyl-CTP)
and pseudouridine-5’-triphosphate (Pseudo-UTP)) was substituted for manufacturer supplied 2X
NTP/CAP during in vitro transcription of modified mRNA. All cells transfected were bovine
fetal fibroblasts (BFF), passage 2-5, cultured at 37°C and 5% CO2 in specified media.
Cell Culture
All target cells were obtained from previously isolated primary cultures (site angelica).
Primary cultures of fibroblasts were established from eight 50-day-old bovine fetuses recovered
from a local abattoir according to previous protocol (Giraldo et al., 2009). With the exception of
the primary culture, the fibroblasts were passaged at 80% confluence. Cultures were passaged by
releasing cells with trypsin (0.25%), counted using a hemacytometer and re-seeded at an initial
concentration of 100,000 cells/flask. These bovine fetal fibroblasts (BFFs) were expanded prior
to treatment in each experiment.
Cell Cryopreservation
Fibroblast cells were frozen and thawed as needed. For cell freezing, the fibroblasts were
resuspendend in DMEM supplemented with 10% BCS and 10% dimethyl sulfoxide (DMSO) and
cooled at 1.0°C/min until reaching -80°C before storage in liquid nitrogen. Approximately
1,000,000 cells were frozen in 1 ml of freezing medium per cryovial. Cells were thawed by
holding the cryovial for 10 sec at room temperature followed by submersion in 38°C water.
Thawed cells were washed once in culture medium before being replated.
RNA Transfection
Lipofectamine® RNAiMax Reagent mediated transfection was carried out within
suggested concentration ranges. Manufacturer protocol suggests 0.5-1.5 μl of Lipofectamine
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reagent per well of 24-well plate leading to the utilization of 1.0 μl Lipofectamine reagent per
well. The protocol suggests 6 pmol of RNA per well of 24-well plate, but various concentrations
were evaluated (1 pmol, 2 pmol, and 4 pmol) according to previous study suggestions (Warren et
al., 2010). RNA 100 ng/µL was diluted per manufacturer instructions and componentes were
pooled and incubated 15 minutes at room temperature prior to being dispensed to culture media.
All cells transfected were bovine fetal fibroblasts, passage 2-5, cultured at 37°C and 5% CO2 in
specified media.
Flow Cytometry
Single cell suspension in PBS without calcium and magnesium in a range of
concentrations (50,000-800,000 cells/mL) were evaluated with SPECIFIC MACHINE. The
relative fluorescence was used as (actual number used from software) for comparison. Mean
intensity?
Cellular Viability
Cellular viability was measured by counting a final number of cells per well following
seeding of constant number of cells for all wells. Cells were counted using a hemocytometer and
phase contrast microscope. The numbers represented the total number of cells within each well at
the time of measurement.
Gene Expression
Cells were extracted from each well followed by mRNA isolation using Dynabeads®
mRNA DIRECT™ Kit. Each sample mRNA was eluted in 15 ul RNase-free water and placed
directly into Bio-Rad iScript™ cDNA Synthesis Kit reaction. The iScript™ kit utilized reverse
transcriptase to transform mRNA into a more stable form, cDNA. The cDNA transcribed from
each sample was evaluated for relevant gene expression with q-PCR.
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Q-PCR
Basic PCR reactions consisted of 25 ul Jumpstart Red Mix, 2 ul forward primer, 2 ul
reverse primer, 10 ul cDNA, and 11 ul dH20 for a total of 50 ul. PCR was performed with a
Hotstart of 94°C (2 min), denature 94°C (30 sec), annealing 60°C (30 sec), extension 72°C (1
min) for 30 cycles followed by a final extension at 72°C (5 min). The final PCR products were
evaluated by gel electrophoresis using 1% agarose gel containing ethidium bromide. The gel was
observed under UV light using BIO-RAD Universal Hood II and density gradient was evaluated
with Quanity One Analysis Software.
Q-PCR procedure utilized EvaGreen® based method. Bio-Rad SsoFast™ EvaGreen®
Supermix was used with primers from Table A.1. Q-PCR was performed with an enzyme
activation at 95°C (1 min) followed by 40 repeats of denature at 95°C (5 sec) and annealing at
60°C (30 sec). A final denature and extension step was performed at 95°C (1 min) and 55°C (1
min) respectively. A melt-curve analysis was carried out by repeating 80 times and increasing
5°C every 10 seconds beginning at 55°C.
Statistical Analysis
Data were analyzed for all preliminary GFP experiments using SAS statistical software,
GLM ANOVA, Levene’s Test for homogeneity of variance. Tests for normality, Shapiro-Wilks,
performed and no transformations were made. Cell viability of modified transfection
experiments were evaluated using an ANOVA under normal assumptions. Relative gene
expression was evaluated with REST statistical software. The program uses the geometric mean
of multiple reference genes to normalize the results against genes of interest (GOI) since ratios
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are used for data evaluation; this is called the Normalization Factor. Individual expressions are
calculated relative to each reference gene and averaged using the geometric mean.
Expression = GOI concentration / GEOMEAN (refConc1, refConc2)
Estimates of concentrations vary exponentially due to the equation form of c = A x eCT.
Experimental Design
Experiment 1
The 24-well plate was prepared with five treatment groups arranged in columns
containing four wells each; Control, No RNA, Low, Medium, High. The “Control” group
contains 5x104 bovine fetal fibroblasts grown in normal growth medium; “No RNA” contains
bovine fetal fibroblasts treated with Lipofectamine lacking ivtRNA. The remaining three
treatment groups contained bovine fetal fibroblasts transfected with three separate concentrations
of ivtRNA-Lipofectamine complex and were cultured in normal growth medium (Dulbecco’s
Modified Eagle Medium (DMEM), 10% Fetal Bovine Serum (FBS), 1% Penicillin/Streptomycin
(P/S)). All wells were seeded at a density of 5x104 of bovine fetal fibroblasts BEZ2 passage 2
(P2). Treatment groups were transfected with specific concentrations of ivtRNA encoding GFP
utilizing lipofectamine as the transfection reagent. GFP relative expression was measured by
flow cytometry 24-hours post-transfection. The measurement of cellular viability was
investigated by determining the number of surviving cells following the transfection of a
constant number of cells in each well.
Experiment 2
A 24-well plate was seeded with BFF P4 bovine fetal fibroblasts at the same density with
normal growth medium. The treatment groups were in columns containing four wells each. The
first column was the control group containing target cells grown under normal conditions. All
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other columns were transfected with 2pmol of GFP ivtRNA per well. The second column was
evaluated at 12 hours post-transfection and remaining columns were evaluated in 12-hour
increments. The treatment groups were as follows: Control, 12-Hour, 24-Hour, 36-Hour, 48Hour, and 60-Hour. The control group was evaluated simultaneously with the 60-Hour treatment
group. Cellular viability was evaluated by counting cells after seeding a constant number of cells
in each well.
Experiment 3
A 24-well plate was seeded with BFF P6 at 5x104 cells per well. The GFP ivtRNA was
used to transfect the target cells over an extended period. The plate was divided into columns
containing four wells each as treatment groups Control, 3-day, 6-day, 9-day, 12-day and 15-day.
All treatment groups other than the control were transfected with 2pmol per well of GFP ivtRNA
every other day. Cells were evaluated for mean fluorescence using flow cytometry and cellular
viability was assessed by cell counting.
Experiment 4
In vitro transcribed OCT4 mRNA was delivered to bovine fetal fibroblasts BFF P5,
followed by examination for endogenous expression. Previous concentration transfection
conditions were used to transfect the cells every other day for 12 days with known pluripotency
factor OCT4. Endogenous bOCT4 gene expression was measured by total RNA extraction and
reverse transcription to cDNA, followed by PCR utilizing bovine OCT4 primers and bovine
PolyA primers as a control.
Experiment 5
Bovine fetal fibroblasts BFF P1 were seeded at a density of 2.5x104 cells per well.
Treatment groups were transfected with modified ivtRNA encoding green fluorescent protein
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(GFP) to evaluate the effects on cellular viability and fluorescence. The cellular viability was
measured by counting a final number of cells after seeding a constant number of cells in all
treatment groups. The control group consisted of bovine fetal fibroblasts cultured in normal
growth medium (DMEM, 10%FBS, 1% P/S). A no RNA (NR) group was held under the same
conditions with the addition of the transfection reagent, Lipofectamine, to account for toxicity
due to the transfection reagent alone. The cells were transfected every other day for 12 days and
were evaluated on days 3, 6, 9 and 12 for viability and fluorescence by flow cytometry.
Experiment 6
This experiment consisted of bovine fetal fibroblasts BFF transfected with modified
ivtRNA cocktails encoding multiple pluripotency factors; 3Factor (KOS) or 4Factor (KMOS)
combinations. The controls were identical to the previous experiments, but treatment groups
were transfected with modified in vitro-transcribed mRNA encoding either three factors (3F:
OCT4, SOX2, KLF4) or four factors (4F: OCT4, SOX2, KLF4, c-MYC). Transfections were
performed every other day for 24 days with

media changed every day. Cells were evaluated

for toxicity by cell counting at the end of the experiment.
Experiment 7
Reprogramming experiments were carried out to evaluate possible change in gene
expression of bovine fetal fibroblasts. The target cells, BFF, were seeded at a density of 1x104
cells per well containing irradiated mouse embryonic fibroblast (iMEF) feeder layers. Cells were
transfected every day with KMOS cocktail containing modified ivtRNA with media changed
daily. Cells were transfected daily for 21 days and cultured in either +/-3i media (+3i contains
three inhibitors PD0325901, CHIR99021, NuP0148 and -3i lacks inhibitors). Pictures were taken
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of all wells on Days 15 and 21. The cells were harvested, counted, and total RNA was recovered
on Day 21. Gene expression was evaluated with quantitative PCR.
Results
Experiment 1: GFP ivtRNA Concentration Evaluation
Bovine fetal fibroblast cells transfected with 2 pmol (medium mRNA concentration)
displayed the highest relative fluorescence with p<0.001 (graph 3.1). The cellular viability
proved to be variable in this particular evaluation, which can be expected with this type of
treatment (graph 3.2).
An optimum ivtRNA concentration was established by selecting the concentration that
yeilded the highest relative fluorescence. The optimum concentration of GFP ivtRNA (2 pmol
per well) was used to transfect cells, and GFP expression was measured every 12 hours post
transfection to determine an expression time course from a single transfection. The relative
fluorescence peaked between 24 and 36 hours post transfection (fig. 3.3). Cell viability decreased
when compared to the control, with transfected treatments having significantly fewer cells than
controls at all time points (fig. 3.4). Cell viability was measured by counting the final number of
cells in each well after seeding a constant number of cells. A notable observation was the
decrease in cellular viability once the Lipofectamine containing the GFP mRNA was added to
the cell culture, when compared to the control group. Each treatment group receiving ivtRNA
transfection experienced a significant amount of cytotoxicity when compared to the control
group (p<0.001).
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Figure 3.1 GFP ivtRNA Concentration Fluorescence

Figure 3.2 GFP ivtRNA Effect on Cellular Viability
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Experiment 2: GFP ivtRNA Time Course Evaluation
Once an optimal concentration of mRNA for transfection was established, the time
course for delivery was addressed. GFP expression was measured every 12 hours posttransfection by the mean fluorescence reading given by flow cytometry. Gene expression peaked
between 24 and 36 hours and slowly declined until the final measurement of 60 hours (Fig. 3.3).
The final measurement was not significantly different from the first 12-hour measurement. No
significant difference was observed between the measurements taken at 24 and 36 hours, but
these measurements were significantly different from the rest.

Figure 3.3 GFP ivtRNA Expression Time Course

33

Figure 3.4 GFP ivtRNA Expression Time Course Cellular Viability

Experiment 3: GFP ivtRNA Extended Time Course Evaluation
Cells were transfected every other day with GFP ivtRNA, and expression was determined
by flow cytometry on days 3, 6, and 9. The GFP was examined every 3 days with flow
cytometry, but cells were no longer viable by day 12. Repeated transfections measured every
three days illustrated greater fluorescence within treatment groups when compared to controls,
but did not increase fluorescence with repeated transfections (fig. 3.5). Cell count of all treatment
groups illustrates a decrease in cellular viability of ivtRNA treated groups when compared to
both controls (fig. 3.6). No difference was observed in viability of all cells treated with ivtRNA
encoding GFP when compared to controls (p=0.9). A significant difference was observed in
fluorescence on all time points when compared to controls (day3 p=0.004, day6 p=0.004, day9
p=0.007, day12 p=0.04).
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Figure 3.5 GFP ivtRNA Expression Extended Time Course

Figure 3.6 GFP ivtRNA Extended Time Course Cellular Viability
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Experiment 4: OCT4 ivtRNA Transfection and Endogenous Activation

A PCR gradient was used to determine an optimal annealing temperature for the bovine
OCT4 primers where no binding to the human OCT4 sequence could occur. As the annealing
temperature increased, the affinity for the human oct4 plasmid decreased (fig. 4.1). The optimal
temperature where the primers bind to the bovine sequence ONLY was then used in subsequent
PCR reactions to determine the presence of endogenous OCT4. As the annealing temperature
increases, the affinity for the human oct4 plasmid decreases. The maximum temperature for the
primers to anneal to the bovine oct4 plasmid—and not to the human oct4 plasmid—is between
58.9 and 63.3 degrees Celsius.
Bovine fetal fibroblasts were transfected with ivtRNA encoding human Oct4 every other
day. RNA was isolated on day 12 and analyzed by semi-quantitative RT-PCR for expression of
the endogenous OCT4. Expression was quantitated by comparing intensities of electrophoresis
bands using poly-adenylate polymerase (PAP) gene for standardization. Expression levels were
expressed as the ratio of intensities of electrophoresis bands. The low concentration of hOCT4
mRNA transfection in the bovine fibroblast cells up-regulated endogenous bOCT4 mRNA
expression measured qualitatively by comparing the intensity per mm2 of the bands present on
the gel (fig.4.2). The ratio of bOCT4 to bPolyA was inverted when compared to the two control
groups (fig.4.2) indicating up-regulation. The ratio (OCT4/PAP) was 0.7 for untreated controls,
0.68 for cells transfected without RNA, and 1.2 for cells transfected with 140 ng per well
ivtRNA encoding hOCT4. Expression was not detected in higher concentration treatments due to
lack of cell survival. PCR conditions previously optimized did not amplify the human OCT4
mRNA, thus detecting the presence of endogenous OCT4. The increased ratio of 1.2 suggests the
stimulation of endogenous OCT4 expression. This can be seen by the inverse of the band
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intensity seen in U5 and U6 when compared to the band intensity ratio of U1&U2 and U3&U4.
There is an inverse in the concentration ratio of the treated group.

Table 3.1 Optimal PCR Conditions for Binding Bovine OCT4 Sequence
Annealing Temp. °C

Bovine OCT4
Plasmid

Human OCT4
Plasmid

Control
No Plasmid

65.0

+

-

-

63.3

++

-

-

58.9

+++

-

-

55.8

+++

+

-

65.0°C

63.3°C

58.9°C

55.8°C

B H C B H C B H C B H C
Figure 3.7 PCR Gradient with Decreasing Annealing Temperature
Figure Legend 3.7
B: Bovine OCT4 plasmid
H: Human OCT4 plasmid
C: Control, no plasmid
(Bovine OCT4 primers used with all
reactions)
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Figure 3.8 Semi-Quantitative RT-PCR displaying endogenous Oct4 up-regulation containing
PAP standardization
Figure Legend 4.2
U1—Control Bovine OCT4
U2—Control Poly-Adenylate Polymerase
U3—No RNA Bovine OCT4
U4—No RNA Poly-Adenylate Polymerase
U5—Low Bovine OCT4
U6—Low Poly-Adenylate Polymerase

Table 3.2 Expression Comparison to Housekeeping Gene
Sample

Primers

Mean Value INT

INT Ratio

Control
Control
No RNA
No RNA
Low
Low

bOCT4
PAP
bOCT4
PAP
bOCT4
PAP

166.64
237.92
157.76
233.13
216.27
182.18

0.7
0.68
1.2

Experiment 5: Modified GFP ivtRNA Transfection Evaluation
The introduction of synthetic mRNA containing modified bases maintains cellular
viability when compared to controls. No difference in viability of all cells treated with synthetic
mRNA encoding GFP was observed when compared to controls (p=0.9). There was a significant
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difference in fluorescence on all time points when compared to controls (day3 p=0.004, day6
p=0.004, day9 p=0.007, day12 p=0.04).
600000

Relative Fluorescence

500000
400000
300000
200000
100000
0
Control

NR

Day 3

Day 6

Day 9

Day 12

Figure 3.9 Relative Fluorescence of Modified GFP ivtRNA Transfection

Modified GFP ivtRNA Cell Viability
450000
400000

Cell Number

350000
300000
250000
200000

150000
100000
50000
0

Control

No RNA

GFP

Figure 3.10 Measurement of Cellular Viability with Modified GFP ivtRNA
Transfection
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Experiment 6: Three Factor and Four Factor Modified ivtRNA Time Course Evaluation
The experiment consisted of bovine fetal fibroblasts transfected with modified synthetic
mRNA encoding pluripotency factors. The controls were identical to the previous experiment,
but treatment groups were transfected with modified synthetic mRNA encoding either three
factors (3F-KOS: OCT4, SOX2, KLF4) or four factors (4F-KMOS: OCT4, SOX2, KLF4, cMYC). The treated cells were transfected every other day and evaluated on day 24 for cellular
viability. No difference was observed in cellular viability in all treatment groups when compared
to controls (p=0.2) (fig. 5.1). The introduction of synthetic mRNA containing modified bases
maintains cellular viability when compared to controls.

Modified 3/4Factor ivtRNA Cell Viability
800000

Cell Number

700000
600000
500000
400000
300000
200000
100000
0

Control

No RNA

4 Factor

3 Factor

Figure 3.11 Measurement of Cellular Viability Post Modified 4F/3F ivtRNA Transfection

Experiment 7: Modified Four Factor Transfection With and Without Inhibitors
Expression of Oct4 was up-regulated in both treatment groups when compared to
controls. The Ct values were evaluated by REST© Software (Pfaffl et al., 2002). The hypothesis
test performed in this program determines whether there is a significant difference between
controls and treatment groups while taking into account reaction efficiency and normalization of
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multiple reference genes. The expression values obtained are a result of the gene of interest
concentration divided by the reference gene concentration. The transfected group lacking
inhibitors (-3i) had a significant increase in Oct4 expression with a value of 334.055 (p=0.007)
when compared to controls. Nanog was not different than controls with expression value of 3.88
(p=0.136). The transfected group including inhibitors (+3i) had a significant increase in Oct4
expression with a value of 55.827 (p=0.004) when compared to controls. Nanog was
significantly down-regulated with an expression value of 0.077 (p=0.020) when compared to
controls. All values where normalized against both PAP and GAPDH, each having a reaction
efficiency near 100%.

Modified 4Factor +/- 3i Cell Viability
250000

Cell Number

200000

150000

100000

50000

0

Control

4F -3i

4F +3i

Figure 3.12 Cell Viability after 21 day transfection with 4F KMOS +/-3i culture media
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Figure 3.13 Relative Expression of Oct4 and Nanog normalized against housekeeping genes PAP and GAP

42

A

B

C

Figure 3.14: BFF cells 15 days culture and daily transfections: (A) 4F -3i Day 15, (B) 4F +3i Day 15, (C) Control Day
15, photos obtained from EVO phase contrast microscope

A

B

C

Figure 3.15: BFF cells 21 days culture and daily transfections: (A) -3i Day 21, (B) +3i Day 21, (C) Control Day 21, photos
obtained from EVO phase contrast microscope

43

Discussion
The addition of exogenous in vitro-transcribed messenger RNA can be successful in
influencing relative gene expression within bovine fetal fibroblasts. These mammalian cells were
capable of incorporating foreign transcripts encoding green fluorescent protein into their normal
cellular processes, which resulted in expression. Relative gene expression was influenced on a
cellular level, indicating the cells ability to be reprogrammed with the addition of exogenous
transcripts.
The increased levels of toxicity and the decrease in cellular viability were possibly due to the
invoked interferon response that is normally initiated when confronted with viral infection.
During cellular reprogramming, exogenous transcription factors are introduced to the
cells of interest to stimulate the production of endogenous transcripts. The presence of
endogenous expression is often difficult to determine, and specific measures are carried out to
distinguish endogenous from exogenous transcripts. If no endogenous stimulation occurs, the
cessation of exogenous transcripts will cause the cell to return to normal gene expression. If, in
fact, endogenous expression is stimulated and exogenous transcripts are halted, the cell should
continue to translate the endogenous sequence. The stimulation of endogenous expression could
be the first steps in complete reprogramming regimes.
Transfection of bovine fibroblast cells with the low concentration of hOCT4 mRNA, upregulated endogenous bOCT4 mRNA expression. It was measured qualitatively by comparing
the intensity per mm2 of the bands present on the agarose gel. Repeated transfections with
ivtRNA resulted in toxicity unrelated to the transfection agent. The increased toxicity was
thought to be in response to the addition of exogenous material invoking an innate immune
response. Cellular viability decreased with introduction of ivtRNA. The control group, NR,
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introduced to the transfection reagent alone did not experience the levels of toxicity of those
treatment groups receiving in vitro transcribed messenger RNA. This addition of exogenous
material mirrors that of viral replication processes, and the toxicity is a natural cellular response.
Experiments utilizing ivtRNA including modified bases reduced cell toxicity of ivtRNA. These
modified bases aid in the decrease of the immune response from the target cells and may
improve the reprogramming process. The cells will maintain their viability and thus survive the
treatment regime. The expected viability concern was eliminated by incorporating these modified
bases. The modified bases decrease the interferon response normally stimulated with the
introduction of exogenous messenger RNA. Further experiments were implemented with
modified ivtRNA encoding pluripotency factors OCT4, SOX2, KLF4 and c-MYC during the
transcription process to enhance reprogramming.
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CHAPTER FOUR
SUMMARY AND CONCLUSIONS
Numerous epigenetic barriers must be overcome during the process of cellular
reprogramming. These barriers have the ability to impede the stimulated up-regulation of
embryonic transcription factors within somatic cells. The complete induction of pluripotency is
the ability to overcome a plethora of epigenetic modifications. These barriers are more difficult
to be carried out than a simple cell lineage switch. There are cells that can be transformed from
one cell type to another, such as B cells into macrophages, with the stimulation from a single
stimulus with 100% efficiency within a 48-hour time period (Xie et al., 2004). This level of
efficiency does not occur within the induction of pluripotency. Mouse fibroblasts were
reprogrammed 18 days after transduction (Li et al., 2011), human ESC derived fibroblasts
displayed tight morphology and distinct colony borders by the end of the second week of
transfection (Warren et al., 2010), and germinal vesicle extract treated cells (GV-ETC) exhibited
colony formation in 7 days (Miyamoto et al., 2009). There are numerous methods and
combinations of stimuli that have improved efficiency, but none have come close to the
previously mentioned 48-hour conversion. A complete understanding of the primary mechanisms
to overcome allows improvement in the reprogramming efficiency.
Transfection with ivtRNA into bovine fetal fibroblasts was not well defined which
required preliminary experiments to be performed. These fundamental experiments outlined the
parameters for transfection. Transcripts encoding GFP were obtained as a template from
Addgene plasmid 26822 containing the sequence for eGFP, or Enhanced Green Fluorescent
Protein. A concentration of ivtRNA for transfection needed to be established. Lipofectamine®
RNAiMAX Reagent protocol suggests 6 pmol RNA per well 24-well plate, as well as a range of
0.6-30 pmol per well. A previous experiment supplied 1200 ng (1.71 pmol) per well in a 6-well
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plate (Warren et al., 2010). A range of concentrations was developed from the suggested
concentrations to establish uniformity of low (1 pmol), medium (2 pmol), and high (4 pmol)
concentrations per well. When scaled down from 6-well format to 24-well format, the final
amount of ivtRNA supplied to each well was low (140 ng), medium (280 ng), and high (560 ng).
The preliminary GFP ivtRNA transfection supported the medium 2 pmol per well concentration
as the optimal concentration which compares to the 1.71 pmol concentration previously
mentioned. However, the endogenous expression of Oct4 in the “unmodified” experiment was
up-regulated within the low concentration group of 1 pmol per well. It is thought this was due to
the increased toxicity of increased concentrations of unmodified ivtRNA which was seen in
previous experiments (Warren et al., 2010).
Once the optimal concentration of 2 pmol ivtRNA per well was established, a time course
for transfections was evaluated. The GFP ivtRNA time course evaluation experiment displayed
peak GFP relative expression between 24 and 36 hours, leading to the decision to transfect every
other day instead of everyday (Warren et al., 2010). The time course was utilized throughout
most experiments, though possibly under an incorrect assumption. The Addgene plasmid 26822
encodes for eGFP, or “enhanced” GFP, which is a recombinant form utilized for its extended
fluorescence and increased stability (Cormack et al., 1996). The peak time of GFP relative
expression measured may be due to an extended ivtRNA half-life when compared to Oct4
ivtRNA half-life. The delay in transfection time when using pluripotency transcription factors
may not have been advantageous. The benefit of daily transfections was not evaluated until the
final experiment, and could possibly have been the source of limited results of reprogramming.
However, the increase or maintained cellular viability post-transfection with modified ivtRNA
was greater than previously reported (Warren et al., 2010). There was no difference between
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transfected cells and control cells or cells treated with the transfection reagent alone. Cellular
viability maintenance may be attributed to the less rigorous transfection regime.
One of the first embryonic transcription factors that must be stimulated is pluripotency
factor OCT4 (Kim et al., 2009b). The decrease in OCT4 expression leads to differentiation and
cell specification; therefore, its stimulation is required for the intricate pluripotency network to
become active (Pesce and Schöler, 2001). The delivery of Oct4 alone induced pluripotency in
adult neural stem cells (Kim et al., 2009b). The abundance of expression in early embryonic
development has long been silenced in a somatic cell line. Methylation of the Oct4 promoter is
the key to managing gene expression. The promoter is highly methylated in somatic cells due to
pluripotency silencing, and completely unmethylated in embryonic cells (Gidekel and Bergman,
2002; Simonsson and Gurdon, 2004). The barriers that are overcome to stimulate this gatekeeper
of pluripotency are necessary for the induction of other embryonic stem cell transcription factors.
Endogenous Oct4 expression was indeed stimulated, indicating the initiation of the
reprogramming process within these bovine fetal fibroblasts. The epigenetic modifications
required for the induction of pluripotency were in fact engaged. Cell morphology was likewise
affected during the process. The cells began to change and form tightly bound groups of cells—
many with distinct borders.
The reprogramming regime including inhibitors (+3i) during culture did not differ from
transfected culture lacking inhibitors (-3i) in terms of up-regulation of embryonic transcription
factor Oct4. The near 100-fold increase in endogenous Oct4 expression is consistent with mouse
fibroblasts reprogrammed to iPSCs compared to mouse ESCs (Zhou and Zeng, 2013). Nanog,
however, was down-regulated in the +3i treatment group. In a previous study, the inclusion of
MEK inhibitor, PD0325901, and GSK3 inhibitor, CHIR99021—in combination during the
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reprogramming of cells that have been recently infected, have had a negative effect on the
required gene expression (Feng et al., 2009). The timing of culture introduction to these
inhibitors may play a role in whether or not the reprogramming is enhanced or inhibited. The
epigenetic remodeling the cells are undergoing must be at an optimal time point for enhancement
to take place. Inhibitor concentration is also a contributing factor for efficient and successful
reprogramming. The concentrations of CHIR99021 and PD0325901 utilized were consistent
with previous studies (Yu et al., 2011) and NuP0148 concentration was estimated due to its
recent development and current concentration evaluation experiments currently being carried out
by NuPotential, LLC. The alteration of this final concentration or combination of concentrations
may still need to be evaluated in future experiments.
The stimulation of endogenous OCT4 expression is encouraging to the reprogramming
process. Somatic cells with the ability to become reprogrammed to be ESC-like cells have the
ability to aid in therapeutic applications and other research endeavors. If these cells are in fact
reprogrammed to a less differentiated state, they might also provide a more efficient nuclear
donor for somatic cell nuclear transfer. This less-differentiated cell would require less epigenetic
modifications by the recipient oocyte. The overall success of SCNT would then increase yielding
positive results for embryos to transfer. An increase in SCNT efficiency would be advantageous
in livestock production schemes.
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APPENDIX A
PROTOCOLS
MMESSAGE MMACHINE® PROTOCOL
1. Thaw frozen reagents. Place RNA Polymerase Enzyme Mix on ice. Vortex the 10X
Reaction Buffer and 2X NTP/CAP to ensure contents are resuspended and place the 2X
NTP/CAP on ice. Centrifuge in microfuge briefly prior to removing caps.
2. Assemble transcription reaction at room temperature. Add the water and ribonucleotides to
the tube prior to adding the 10X Reaction Buffer, followed by the addition of linear DNA
template and Enzyme Mix.
a. 10 µl 2X NTP/CAP, 2 µl 10X Reaction Buffer, 6 µl (0.1-1ug) Linear DNA
template, 2 µl Enzyme Mix
3. Mix thoroughly by gently flicking the tube or pipetting up and down. Centrifuge briefly to
bring the reaction to the bottom of the tube.
4. Incubate at 37°C for 2 hours for maximum yield (1 hour incubation has an 80% yield)
5. OPTIONAL: Add 1 µl TURBO DNase and mix thoroughly. Incubate 15 min at 37°C to
remove template DNA.
6. Reaction goes immediately into Poly(A) Tailing Kit
AMBION® POLY(A) TAILING KIT PROTOCOL
1. Begin with a completed, room temperature, DNase-treated mMessage mMachine reaction
(20 µl in 1.5ml tube). DO NOT add EDTA to the reaction to inactivate the DNase.
2. Remaining at room temperature, add the following reagents in the order they are listed to
the 20 µl mMessage mMachine reaction:
a. 20 µl mMessage mMachine reaction, 36 µl Nuclease-free water, 20 µl 5X E-PAP
Buffer, 10 µl 25 mM MnCl2, 10 µl 10 mM ATP
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3. Remove 0.5 µl of the reaction prior to adding the enzyme to run as a control on a gel
against the tailed reaction.
4. Add 4 µl of E-PAP and mix gently. The final reaction should be 100ul.
5. Incubate for 1 hour at 37°C.
6. Reaction can go directly into the MEGAclear™ Kit procedure or can be placed on ice or
stored at -20°C until for later use.
7. During the incubation period, prepare a denaturing agarose gel for electrophoresis. The
agarose-formaldehyde gel is used to compare the tailed reaction to the untailed original.
a. Heat the samples to 75°C for 10 minutes.
b. Load the samples onto the gel and run in 1X MOPS buffer at 5 volts/cm until the
bromophenol blue dye is near the bottom of the gel.
c. Examine in a UV light. The tailed reaction should be approximately 150 bases
longer than the untailed original.
FOMALDEHYDE AGAROSE GEL ELECTROPHORESIS
1.2 g agarose
10 ml 10X FA gel buffer (components listed below)
Add RNase-free water to 100ml
1. Heat to melt agarose. Cool to 65°C in a water bath.
2. Add 1.8 ml of 37% (12.3 M) formaldehyde and 1 ul of a 10 mg/ml ethidium bromide stock
solution. Mix thoroughly and pour into gel mold.
3. Equilibrate the gel for at least 30 minutes in 1X FA gel running buffer prior to running the
gel.
4. Run the gel at 5-7 V/cm in 1X FA gel running buffer.
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MEGACLEAR™ KIT PROCEDURE
1. Begin with 100 μl Poly(A) Tailing Reaction (or bring RNA sample up to 100 μl by adding
Elution Solution and mix gently).
2. Add 350 μl of Binding Solution Concentrate and mix gently by pipetting.
3. Add 250 μl of 100% ethanol and mix gently by pipetting.
4. Insert a filter cartridge into a Collection and Elution tube supplied by the manufacturer.
5. Apply the RNA sample to the filter cartridge.
6. Centrifuge at 10,000-15,000 x g for 1 minute to pass mixture through the filter.
7. Discard flow-through and reuse the Collection and Elution Tube during the following wash
steps.
8. Be sure ethanol has been added to the wash solution before use. Apply 500 µl Wash
Solution and centrifuge at 10,000-15,000 x g for 1 minute to pass the Wash Solution
through the filter.
9. Repeat with a second 500 µl Wash Solution.
10. Discard flow-through and centrifuge for 30 seconds at 10,000-15,000 x g to remove any
Wash Solution.
11. Elute RNA with 50 µl of Elution Solution
a. OPTION 1: Place filter cartridge into a new Collection/Elution Tube. Apply 50 µl
Elution Solution to the center of the filter and close the cap. Incubate in heat block
at 65-70°C for 5-10 minutes. Recover eluted RNA by centrifuging for 1 minute at
10,000-15,000 x g. *To maximize recovery, repeat with a second 50 µl of elution
solution in the same tube.
b. OPTION 2: Pre-heat 110 µl of Elution Solution to 95°C. Apply 50 µl of pre-
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heated Elution Solution to the center of the filter and close the cap. Centrifuge for
1 minute at 10,000-15,000 x g. *To maximize recovery, repeat with a second preheated 50 µl of Elution Solution into the same tube.
LIPOFECTAMINE® RNAiMAX REAGENT TRANSFECTION PROTOCOL
1. Plate target cells 24-hours prior to transfection in 500 µl growth medium each well of a 24well plate. Cell should be 50-70% confluent for transfection.
2. Dilute ivtRNA in 50 ul of Opti-MEM® I Medium without serum per well in a 15 ml
conical tube and mix gently. Label as Tube 1.
3. Gently mix Lipofectamine® RNAiMAX Reagent prior to use. Dilute 1 µl of
Lipofectamine® RNAiMAX Reagent in 50 µl of Opti-MEM® I Medium per well in a
separate 15 ml conical tube. Label as Tube 2.
4. Combine the contents of Tube 2 into the contents of Tube 1 and mix gently. Incubate for
15 minutes at room temperature.
5. Add adequate amount of RNA-Lipofectamine® complexes to each well and mix gently by
rocking the plate back and forth several times. The total volume should be roughly 600
µl.
6. Incubate in CO2 incubator at 37°C.
7. Change medium 4-6 hours after transfection.
8. Repeat transfection as desired.
R&D SYSTEMS® iMEF PLATING PROTOCOL
Catalog Number: PSC001, irradiated primary mouse embryonic fibroblast cells at passage 3,
approximately 6 x 106 cells per vial, stored in LN
*Feeder layers should be plated at least 24 hours prior to seeding target cells.
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1. Coat surface of dish with 0.1% sterile gelatin for 15 minutes.
2. Warm iMEF medium (high glucose DMEM, 10% fetal bovine serum, 2 mM L-Glutamine)
to 37°C.
3. Thaw the cells quickly by warming vial in 37°C water bath. Immediately transfer contents
of vial to 15 mL conical tube containing 5 mL of pre-warmed iMEF medium. Rinse vial
with 1 mL of pre-warmed medium to ensure removal of all cells from vial.
4. Pellet cells at 200 x g for 5 minutes.
5. Remove excess gelatin from wells immediately prior to plating iMEF cells.
6. Resuspend iMEF cells in pre-warmed iMEF medium and transfer appropriate density of
cells depending on the surface area of dish (approximately 1 x 106 cells/60 mm plate).
7. Incubate overnight in a 5% CO2 incubator at 37°C.
DYNABEADS® RNA ISOLATION PROTOCOL
1. Harvest cells from culture flask and pellet as per standard procedure
2. Add 300 µl of Lysis/Binding buffer (100 mM Tris-HCL [pH 7.5], 500 mM LiCl, 10 mM
EDTA [pH 8], 1% LiDS, 5 mM dithiothreitol [DTT]) to fresh cell pellet.
3. DNA-shearing step is advised if sample is greater than 500,000 cells. Strip cells using a 21gauge needle and a 1 ml syringe.
4. Prepare 50 µl Dynabeads Oligo (dT)25 per manufacturer instructions (Invitrogen Dynal As,
Oslo, Norway, Cat.no. 610.11/610.12).
5. Add sample lysate to pre-washed Dynabeads (pre-washed in lysis/binding buffer).
6. Resuspend beads completely into sample lysate and incubate with continuous mixing
(rolling mixer) for 5 minutes at room temperature. This allows the polyA tail to hybridize
to the beads.
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7. Place the vial on the magnet for 2 min and remove supernatant. If viscous, increase time to
10 minutes.
8. Wash beads/mRNA complex twice in 600 µl Washing Buffer A (10 mM Tris-HCl [pH
7.5], 0.15 M LiCl, 1 mM EDTA, 0.1% LiDS) at room temperature. Place on magnet to
separate beads from solution between each wash step.
9. Wash beads/mRNA complex in 300 µl Washing Buffer B (10 mM Tris-HCl [pH 7.5], 0.15
M LiCl, 1 mM EDTA) at room temperature. Use the magnet to separate the beads from
the solution.
10. Elute the RNA from the beads by adding 15 µl of nuclease-free water, incubate at 70°C
for 2 min. Immediately place tube on magnet, and transfer supernatant to a new RNasefree tube.
11. Use sample directly into cDNA protocol.
iSCRIPT CDNA SYNTHESIS PROTOCOL
1. Add 4 µl of iScript reaction mix and 1 µl of reverse transcriptase to a 15-µl RNA sample
from previous DYNABEADS isolation in a PCR tube (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA).
2. Place PCR tubes into thermocycler and run cDNA protocol.
a. 5 min at 25°C, 30 min at 42°C, and 5 min at 85°C, (final hold at 4°C)
RNEASY® PLUS MINI KIT (QIAGEN)
1. Harvest cells by trypsinization and pellet. Completely remove supernatant.
2. Disrupt cells with the addition of Buffer RLT Plus. Loosen pellet by flicking prior to
adding 350 µL Buffer RLT. Mix by vortexing or pipetting up and down.
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3. Homogenize lysate by passing it through a 20-gauge needle 5 times in an RNase-free 1ml
syringe.
4. Transfer homogenized lysate to a gDNA Eliminator spin column placed within 2 ml
collection tube. Centrifuge 30 seconds at 8000 x g and discard column. Collection tube
should contain flow-through to be used in following steps.
5. Add 350 µl of 70% ethanol to the flow-through in the collection tube. Mix by pipetting
up and down.
6. Transfer 700 µl of sample to RNeasy® spin column placed within a 2 ml collection tube
and close lid. Centrifuge for 15 seconds at 8000 x g. Discard flow-through.
7. Add 700 µl Buffer RW1 to the RNeasy® spin column placed into previous collection
tube. Close lid and centrifuge for 15 seconds at 8000 x g. Discard flow-through.
8. Add 500 µl Buffer RPE to RNeasy® spin column and close lid. Centrifuge for 15
seconds at 8000 x g. Discard flow-through.
9. Add 500 µl Buffer RPE to RNeasy® spin column and close lid. Centrifuge 2 minutes at
8000 x g to ensure removal of ethanol. Remove column carefully not coming in contact
with flow-through.
10. Place RNeasy® spin column into a new 2 ml collection tube and add 30 µl RNase-free
water directly to spin column membrane. Close lid and centrifuge for 1 minute at 8000 x
g for RNA elution. Repeat with an additional 30 µl to maximize recovery.
RT-PCR PROTOCOL
1. Each reaction is carried out in a total of 50 µl. Mix 25 µl of JumpStart™ REDTaq®
ReadyMix™ PCR Reaction Mix (Sigma Aldrich), 2 µl of (10 mM) forward primer, 2 µl
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of (10 mM) reverse primer, 11 µl of water, and 10 µl of sample cDNA. Prepare master
mixes prior to avoid repeated pipetting.
2. Place tubes into thermocycler with the following program:
a. Thermocycler Program
Hotstart
94°C
Denature
94°C
Anneal
60°C
Extend
72°C
30 CYCLES
Final Ext
72°C
Hold
4°C

2 minutes
30 seconds
30 seconds
1 minute
5 minutes
indefinitely

b. Annealing temperature is specific to primers used in reaction.
3. Remove tubes from thermocycler and add 25 µl of each PCR product to a 1% agarose gel
for electrophoresis.
qRT-PCR PROTOCOL
1. Set up plate template.
2. Prepare master mixes for each gene. Each reaction is carried out in a 20 µl reaction (10 ul
of SsoFast™ Evagreen Supermix (Bio-Rad Laboratories, Inc. Hercules, CA, USA), 4 µl
of nuclease-free water, 1 µl of (10 mM) forward primer, 1 μl of (10 mM) reverse primer,
and 4 µl of sample cDNA, calibrator cDNA, or water as negative control.
3. Add 20 µl of each reaction into a single well of a 96-well plate with the designated plate
set-up. Cover with sealing tape supplied by plate manufacturer. Be sure to completely
seal each well using the rubber scraper or tool provided.
4. Place 96-well plate into thermocycler and run the following program:
a. Thermocycler Program
Cycle Repeats
Step
1
1
1
2
40
1

Time
1 min
5 sec
65

T°
95
95

Melt Curve

3
4
5

1
1
80

2
1
1
1

30 sec
1 min
1 min
10 sec

60
95
55
55

yes, +5° each repeat

5. Evaluate post-run data for analysis and melting curve. If a calibrator dilution was
performed, evaluate Standard Curve Efficiency, PCR Amp/Cycle graph, and Melt Curve
Analysis.
Plasmid Preparation
Stab cultures containing plasmids encoding desired sequences were obtained from
Addgene. The cultures were streaked on agar plates containing ampicillin 100ug/ml
concentration. Clones were chosen from each plate by inserting a pipette tip into a single colony
and inserting it into 3ml of Terrific Broth containing ampicillin 100ug/ml in a 15 ml culture tube.
The selected clones were prepared as mini-preps with overnight culture at 37° C shaking at 225
RPM in C24 Incubator Shaker (New Brunswick Scientific, Classic Series).
Mini Prep Isolation
All tubes were cloudy post-incubation, indicating growth of the selected clones. Minipreps were performed on all tubes using SIGMA GenElute Plasma Mini Prep Kit. Cells were
pelleted from 1.5 ml of previous overnight culture for 1 minute at 12,000 x g in table top
centrifuge (Thermo, Heraeus Pico 17 Centrifuge). Supernatant was discarded and cells were
resuspended by pipetting up and down in 200 μl of Resuspension Solution provided in the kit.
The cells were then lysed with the addition of 200 μl of Lysis Solution and inverting the tubes
gently to mix. The tubes were then allowed to equilibrate for ≤ 5 minutes. The cleared lysate was
then prepared for isolation with the addition of 350 μl of Neutralization Solution and inverted 4-6
times to mix. The tubes were then centrifuged at maximum speed of 13,000 x g for 10 minutes.
The binding column was prepared by adding 500 μl of Column Preparation Solution and
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centrifuged at 12,000 x g for 1 minute. The cleared lysate was then transferred to the prepared
binding columns to bind the plasmid DNA for isolation. The column containing the cleared
lysate was centrifuged for 1 minute at 12,000 x g and the flow-through was discarded.
Contaminants were removed by adding 750 μl of Wash Solution (ethanol added prior to first use
of kit) to the column followed by centrifugation at 12,000 x g for one minute. The flow through
was discarded and was centrifuged for an additional minute to remove to dry the column. Each
column was transferred to a new collection tube and the plasmid DNA was eluted in 75ul of
molecular grade water and was stored at -20°C.
Clone Selection
Diagnostic cuts in the DNA were performed with restriction enzyme XbaI on each clone.
A master mix was prepared when applicable (buffer provided by manufacturer, molecular grade
water, XbaI restriction enzyme) for all mini-prep isolations. The master mix was then divided
and 85ul was placed in 12 separate 1.5 ml centrifuge tubes followed with the insertion of 15ul
DNA for each clone. The digest was performed in a hot water bath of 37°C for 1 hour and 15
minutes. The tubes were removed from the water bath and 15ul of loading buffer was added to
each tube and mixed gently by pipetting up and down. A 1% agarose gel was prepared and 25 μl
of each digest were loaded into the wells for electrophoresis evaluation. The bands were
evaluated with the additional 1 kilobase (1Kb) and 100 base pair (100bp) ladders added to the
outside lanes. The correct diagnosis was reached with the GFP plasmid dropping out a 904 bp
sequence and OCT4 plasmid dropping out a 1200 bp sequence.
Clones were selected and were removed from the refrigerator and 2 ml of Terrific Broth
containing ampicillin was added. The cultures were allowed to shake at 225 RPM at 37°C for 1
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hour. The remaining 50 ml of broth was then added and the culture was incubated overnight at
the same conditions in a 500 ml Erlenmeyer flask.
Midi Prep Plasmid Purification
Qiagen Midi Preps were then carried out by pelleting 50 ml of overnight culture at
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x g for 15 minutes at 4°C. Supernatant was removed and the pellet was resuspended in 4 ml of
Buffer P1, followed by the addition of 4 ml of Buffer P2. The mix was thoroughly made
homogenous by inverting vigorously 5 times followed by 5-minute incubation at room
temperature. The QIAfilter Cartridge was prepared during this incubation period. Buffer P3 was
added at 4 ml and mix thoroughly by inverting vigorously 5 times. The lysate was poured into
the barrel of the QIAfilter Cartridge and was incubated for 10 minutes at room temperature.
QIAGEN-tip 100 was equilibrated by adding 4 ml of Buffer QBT. This buffer was released by
gravity flow. The lysate in the barrel of the QIAfilter Cartridge was expelled into the prepared
QIAGEN-tip 100 by inserting the plunger into the barrel and filtering the lysate into the prepared
tip. The cleared lysate was allowed to flow through the tip by gravity flow, followed by 2 x 10
ml wash with Buffer QC. The DNA was eluted with 5 ml of Buffer QF and precipitated with the
addition of 3.5 ml of room-temperature isopropanol. The solution was mixed and centrifuged at
15,000 x g for 30 minutes at 4°C. The supernatant was decanted and the DNA pellet was washed
with 2 ml of room temperature 70% ethanol and centrifugation at 15,000 x g for 10 minutes. The
supernatant was decanted and the pellet was allowed to air-dry for 5-10 minutes. The DNA was
re-dissolved in 500 μl TE for each preparation and placed in -20°C for storage. DNA was
quantified by absorbance by SmartSpec™ Plus Spectrophotometer (BioRad) and TE buffer.
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Diagnostic restriction digests were performed on Midi Preps for validation using XbaI
restriction enzyme. The digests were performed overnight at 37°C in a warm water bath. The
digests were evaluated using gel electrophoresis and a 1% agarose gel.
Synthesizing Messenger RNA
Plasmids containing template sequence were linearized using restriction enzyme XbaI.
The restriction digest was terminated with the addition of 1/10th the volume of 3 M Na acetate
and 2 volumes of ethanol. The solution was mixed well and stored in -20°C for 15 minutes. The
DNA was pelleted by centrifugation at 13,000 x g for 15 minutes. The supernatant was removed
and the tube centrifuged again, and any residual fluid was removed with a fine-tipped pipet. The
pellet was resuspended in 6 μl TE and was carried over into the mMESSAGE mMACHINE Kit
(High Yield Capped RNA Transcription Kit). The reaction was performed in a total of 20 μl,
including 10 μl of 2X NTP/CAP, 2 μl 10X Reaction Buffer, 6 μl linear template DNA, and 2 μl
of Enzyme Mix. The solution was mixed by gently flicking the tube and was incubated for 2
hours at 37°C in a warm water bath.
The previously completed 20ul reaction was carried over to the Poly (A) Tailing Kit
(Applied Biosystems AM1350) for further RNA packaging. The tailing agents were added in
order (36 μl Nuclease-free water, 20 μl 5X E-PAP Buffer, 10 μl 25 mM MnCl2, and 10 ul mM
ATP, 4 μl E-PAP) to the room temperature 20ul mMessage mMachine reaction yielding a total
of 100 μl. This tailing reaction was incubated at 37°C for 1 hour in a warm water bath.
The tailing reaction was purified using MEGAclear Kit (Applied Biosystems AM1908).
The RNA sample was first subjected to 350 μl of Binding Solution Concentrate and was mixed
gently by pipetting up and down. 250 μl of 100% ethanol was added and mixed gently. A filter
cartridge was inserted into a Collection Tube supplied by the kit. The RNA mixture was loaded
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into the filter cartridge and is centrifuged for 1 minute at 13,000 x g in tabletop centrifuge. The
flow-through was discarded and the same Collection Tube was used for the washing steps. The
Wash Solution (previously added ethanol as directed) was applied 2 x 500 μl with centrifugation
and discarding flow-through. The tubes were centrifuged once again to ensure removal of all
wash solution. The RNA was then eluted into a new Collection Tube by adding 50 μl of prewarmed (95°C) TE to the cartridge. The tube was centrifuged at 13,000 x g for 1 minute. This
step was repeated within the same collection tube to maximize RNA recovered.
The ivtRNA was then quantified using NanoVue Spectrophotometer using TE as the
blank for the machine. The solution was then diluted with an adequate volume of TE to obtain a
working concentration of 100 ng/ml.
Expansion of Cell Cultures
Established bovine fetal fibroblast cell line BEZ2 (passage 2-5) was removed from liquid
nitrogen and quickly placed in warm water bath at 37°C until thawed. Cells were removed from
the cryovial and placed into 15ml conical tube containing 5ml of Dulbecco’s Modified Eagle
Medium (DMEM), 10% Fetal Bovine Serum (FBS), and 1% penicillin/streptomycin (P/S). The
cryovial was then rinsed with 1ml of the same medium to ensure removal of all cells. The conical
tube was then centrifuged at 350 x g for 5 minutes to establish a cell pellet. The supernatant was
removed and the cells were resuspended in 10 ml of medium and placed into a T75 for
expansion. The T75 culture flask was incubated in 5% CO2 at 37°C for two days. Once the cells
were approaching confluency they were passaged with Trypsin (0.25 EDTA) and plated into 24well plates at recommended seeding density of 50,000 cells per well. The plates were then
incubated in 5% CO2 at 37°C for 24 hours.
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Lipofectamine Transfections
Previously plated bovine fetal fibroblasts reached 70% confluency and were ready to be
transfected. Specific ivtRNA was diluted in Opti-MEM I Medium at in 15ml conical tubes.
Lipofectamine RNAiMAX Reagent was diluted 1ul per 50ul Opti-MEM I Medium in a 15 ml
conical tube. The diluted RNA complex was then combined with the Lipofectamine RNAiMAX
Reagent and incubated for 15-20 minutes at room temperature. The RNAi-duplex-Lipofectamine
RNAiMAX Reagent complexes were added to each well containing cells for transfection. The
final volume was roughly 600ul per well. The plate was moved back and forth several times to
ensure even distribution of ivtRNA-Lipofectamine mixture over all cells attached to well. The
cells were incubated in 5% CO2 at 37°C for 24 hours and all media was changed daily.
Flow Cytometry
Culture medium was aspirated from all wells, followed by a wash with PBS without calcium and
magnesium. PBS was aspirated and cells were detached using Trypsin (0.25 EDTA). Normal
growth medium containing serum was added to inactivate the Trypsin. The contents of each well
were transferred into labeled 1.7ml centrifuge tubes. The cells were centrifuged at 400 x g for 8
minutes. The supernatant was completely aspirated and the cells were resuspended in 1ml PBS
(without calcium and magnesium). A small volume (10 μl) was removed from each sample and
placed in 90 μl of PBS for cell counting. The flow cytometer was prepared for sampling by the
routine setup protocol prior to running any samples. Once the flow cytometer was ready, each
sample was evaluated for 5 minutes with slow fluidics settings.
RNA Isolation
The cells were trypsinized from each well and treatment groups were combined into one
15ml tube each for unmodified ivtRNA experiments. The cells were isolated and evaluated by

71

well for all other experiments. The cells were pelleted and resuspended in 1 ml PBS without
calcium and magnesium. This volume was transferred to 1.5 ml tubes and pelleted again at 400 x
g for 8 minutes using a table top centrifuge. The mRNA was harvested using DYNA beads
following the “mini” protocol. The mRNA was eluted in 15 ml of dH2O, which went
immediately into iScript to be converted into cDNA per manufacturer instructions, yielding a
final volume of 20 μl. The final 20 μl reaction was divided in half for subsequent PCR reactions.
Polymerase Chain Reaction
PCR was used to determine the endogenous expression of bovine OCT4 compared to
exogenous expression of human OCT4. Each PCR reaction consisted of 25 μl Jumpstart Red
Mix, 2 μl forward primer, 2 μl reverse primer, 10 μl cDNA, and 11 μl dH20 for a total of 50 μl.
The final PCR products were evaluated by gel electrophoresis using 1.2% agarose gel including
100bp ladder on the outside lanes.
Establishing 4-Factor and 3-Factor Cocktails
A KMOS (KLF4, cMYC, OCT4, SOX2) and KOS (KLF4, OCT4, SOX2) cocktails were
prepared using the working concentrations of each of the ivtRNA solutions. OCT4 was held at
3X the concentration of the other factors.
Calibrator Development
A positive control is required during the analysis of gene expression through quantitative
PCR. This positive control normally comes in the form of a calibrator. Total RNA was isolated
from BEZ2 P7 using RNeasy® Plus Mini Kit from Qiagen per manufacturer instructions. The
RNA was immediately converted into cDNA using iScript. The calibrator is made up of cDNA
from the target cells “spiked” with purified PCR product (QIAquick PCR Purification Kit)
encoding specific genes. These genes include both the genes of interest, OCT4, SOX2, and
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NANOG, as well as housekeeping genes PAP and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). The calibrator contains genes of interest at a final concentration of 2pg/μl and the
housekeeping genes at a final concentration of 0.2pg/μl.
qPCR
Quantitative PCR was used to evaluate gene expression in the target cells. Total RNA
was extracted from cells in all wells using DYNA beads according to the manufacturer’s
instructions. The final elution into 15ul dH2O was placed directly into a complementary DNA
reaction following the manufacturer’s instructions, with a final volume of 20ul per sample. Prior
to setting up PCR reactions, each sample was diluted with the addition of 50ul dH2O. Each PCR
reaction contained 4ul of sample cDNA. Measurements were carried out in triplicates and a notemplate reaction as a negative control. Amplification, standard curves and gene expression
efficiency were normalized against housekeeping genes PAP and GAPDH as internal controls.
Table A.1 PCR Primers
Primer

Sequence

Amplicon
Length

Accession #

Oct4 sense

GGTTCTCTTTGGAAAGGTGTTC

223

NM_174580.2

Oct4 antisense

ACACTCGGACCACGTCTTTC

Sox2 sense

AGGACTGAGAGAAAGAAGAAGAG

164

NM_001105463.2

Sox2 antisense

AAGAAAGAGGCAAACTGGAATC

Nanog II sense

AATTCCCAGCAGCAAATCAC

215

NM_001025344.1

Nanog II antisense

CCCTTCCCTCAAATTGACAC

Poly A sense

AAGCAACTCCATCAACTACTG

169

X63436

Poly A antisense

ACGGACTGGTCTTCATAGC

GAPDH sense

CCTTCATTGACCTTCACTACATGGTCTA

127

U85042

GAPDH antisense

TGGAAGATGGTGATGGCCTTTCCATTG
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Table A.2: GFP ivtRNA Quantification

GFP (1)

Concentration (ug/ml)

A260/A280

656.8

2.477

Table A.3 ivtRNA Concentrations
Volume per well (μl)

Low

RNAi duplex concentration
*24-well plate
1 pmol (140ng)

Medium

2 pmol (280ng)

2.8

High

4 pmol (560ng)

5.6

1.4

Table A.4 Plasmid DNA Quantification
Concentration (ug/ml)

A260/A280

OCT4

12.3314

1.7169

GFP

13.2331

1.7738

Table A.5: hOCT4 ivtRNA Spectrophotometer Quantification
Concentration (ug/ml)

A260/A280

hOCT4 (1)

596.0

2.656

hOCT4 (2)

592.4

2.649
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Table A.6 ivtRNA Concentrations
µl per well

Low

RNAi duplex concentration
*24-well plate
1 pmol (140ng)

Medium

2 pmol (280ng)

2.8

High

4 pmol (560ng)

5.6

1.4

Table A.7 Plasmid DNA Quantification
Concentration (ug/ml)

A260/A280

KLF4

12.3314

1.7169

c-MYC

13.2331

1.7738

SOX2

65.7967

1.9400

Table A.8: SOX2, KLF4, cMYC ivtRNA Quantification
Gene

Concentration (ug/ml)

A260/A280

SOX2

259.2

3.057

KLF4

402.4

2.661

cMYC

228.4

2.266

OCT4

260.3

2.936
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Table A.9 Purified PCR Products
Gene

Concentration (ng/ml)

A260/A280

OCT4

4.7

1.500

SOX2

4.9

1.485

NANOG

15.5

1.667

PAP

14.8

1.561

GAPDH

17.0

1.735
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APPENDIX B
MEDIA FORMULATIONS AND STOCK SOLUTIONS
Table B.1 List of Plasmids
Plasmid

Clones Selected
From Plates

Clones Used for
Mini-Prep

Clone Selected

26822pcDNA3.3_GFP

1-6

1-6

1

26816pcDNA3.3_OCT4

1-6

1-6

1

26817pcDNA3.3_SOX2

1-6

1-3, 6

2

26818pcDNA3.3_cMYC

1-6

1-6

6

26815pcDNA3.3_KLF4

1-6

1-6

1

NORMAL GROWTH MEDIUM
DMEM (Dulbecco’s Modified Eagle Medium)
10% FBS (Fetal Bovine Serum; or Bovine Calf Serum (BCS) for non-experimental cell culture)
1% P/S (Penicillin/ Streptomycin)
iMEF CULTURE MEDIUM
DMEM
15% FBS
1% L-Glutamine
1% P/S
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MODIFIED bESC MEDIUM
DMEM
15% FBS
1% L-Glutamine
1% P/S
1000 U/ml LIF
4 ng/ml bFGF
MODIFIED bESC MEDIUM +3i
DMEM
15% FBS
1% L-Glutamine
1% P/S
1000 U/ml LIF
4 ng/ml bFGF
0.5 µM PD0325901
3 µM CHIR99021
1.8 µM NuP0148

10X FA Gel Buffer Composition
200 mM 3-[N-morpholino]propanesulfonic acid (MOPS) (free acid)
50 mM sodium acetate
10 mM EDTA
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1X FA Gel Running Buffer Composition
100 ml 10X FA gel buffer
20 ml 37% (12.3 M) formaldehyde
880 ml RNase-free water

Example:
Tube 1: 50ul OptiMEM x 17 wells = 850ul OptiMEM
2.8ul ivtRNA x 17 wells = 47.6ul ivtRNA
Tube 2: 50ul OptiMEM x 17 wells = 850ul OptiMEM
1ul Lipofectamine x 17 wells = 17ul Lipofectamine
The contents of Tube 2 is added to Tube 1 and incubated for 15-20 minutes. A volume of 103.8ul
of mixture is added to each well after incubation is complete.
Note* Transfections were done as forward transfections described by the Invitrogen Lipofectamine RNAiMAX
Reagent protocol. The reverse transcription method was evaluated yielding similar results (data not shown). Due to
the need of repeated transfections, the forward protocol was selected for all experiments.
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OCT4 Calibrator Evaluation

Figure B.1 OCT4 PCR Amp/Cycle Graph of SYBR-490

Fig. B.2 OCT4 Standard Curve
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Figure B.3 OCT4 Melting Curve
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SOX2 Calibrator Evaluation

Figure B.4 SOX2 PCR Amp/Cycle Graph for SYBR-490

Figure B.5 SOX2 Standard Curve
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Figure B.6 SOX2 Melting Curve

83

NANOG Calibrator Evaluation

Figure B.7 Nanog PCR Amp/Cycle Graph for SYBR-490

Figure B.8 Nanog Standard Curve
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Figure B.9 Nanog Melting Curve
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PAP CALIBRATOR EVALUATION

Figure B.10 PAP PCR Amp/Cycle Graph for SYBR-490

Figure B.11 PAP Standard Curve
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Figure B.12 PAP Melt Curve
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GAPDH CALIBRATOR EVALUATION

Figure B.13 GAPDH PCR Amp/Cycle Graph for SYBR-490

Figure B.14 GAPDH Standard Curve
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Figure B.15 GAPDH Melt Curve
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